Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.40 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13729416 | 0.98 | CYP1A2 (0.52) | CYP1A2CNR2HPGDCHRM4SMN1; SMN2 | |
| SCHEMBL13466378 | 0.84 | DRD2 (0.47) | CYP1A2PANK3OGANPC1ALDH1A1 | |
| SCHEMBL20045994 | 0.82 | HRH3 (0.50) | CYP1A2PANK3OGAALDH1A1 | |
| SCHEMBL20203428 | 0.82 | BPTF (0.57) | CYP1A2HTTPANK3ALDH1A1MAPK1 | |
| SCHEMBL11960318 | 0.82 | ALDH1A1 (0.51) | CNR2HPGDSMN1; SMN2HTTNPC1 | |
| SCHEMBL14503215 | 0.82 | CYP1A2 (0.75) | CYP1A2CNR2HPGDCHRM4SMN1; SMN2 | |
| SCHEMBL22006820 | 0.81 | NPC1 (0.50) | SMN1; SMN2HTTPANK3OGANPC1 | |
| SCHEMBL20046660 | 0.80 | LMNA (0.37) | CYP1A2SMN1; SMN2HTTPANK3OGA | |
| SCHEMBL20255432 | 0.79 | HRH4 (0.39) | CYP1A2HPGDCHRM4SMN1; SMN2HTT | |
| SCHEMBL18291669 | 0.79 | HRH3 (0.46) | PANK3OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | NPY4R, NPY1R, NPY5R | CYP1A2 1621/4885CNR2 15/4885HPGD 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.